Pacira BioSciences Sells iovera° Business to Zimmer Biomet for Up to $140M
Event summary
- Pacira BioSciences to divest its iovera° business to Zimmer Biomet for up to $140M, including $70M upfront.
- Transaction expected to close in Q3 2026, with potential milestone payments through December 31, 2031.
- Companies will collaborate on advancing the spasticity program, with Pacira eligible for incremental compensation upon successful study completion and regulatory approval.
- Proceeds from the deal will strengthen Pacira’s balance sheet, including paying down its senior secured revolving credit facility.
The big picture
Pacira’s divestiture of iovera° to Zimmer Biomet reflects a strategic shift towards biopharmaceutical innovation, aligning with broader industry trends of specialization and focus. The $140M deal underscores the value of non-opioid pain therapies in an increasingly competitive medical technology landscape. Zimmer Biomet’s global scale and commercialization expertise position it to expand iovera°’s reach, while Pacira aims to streamline its portfolio and enhance financial flexibility.
What we're watching
- Strategic Focus
- How Pacira’s divestiture aligns with its transition into an innovative biopharmaceutical company and its '5x30' strategy.
- Execution Risk
- Whether Zimmer Biomet can successfully integrate and expand the iovera° business globally to unlock its full potential.
- Financial Impact
- The pace at which Pacira deploys the upfront proceeds to strengthen its balance sheet and reduce debt.
Related topics